Dr. Isabelle Vande Broek discusses the results of two recent subgroup analyses of the IKEMA trial
Dr. Isabelle Vande Broek, VITAZ hospital, Sint-Niklaas
In this episode, Dr. Isabelle Vande Broek will discuss the results of two recent subgroup analyses of the IKEMA trial, assessing isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma.
This HematoTalk is brought to you by the publisher of the Belgian Journal of Hematology (BJH) in partnership with SANOFI.
SUBSCRIBE TO BJH HEMATALKS SERIES